Navigation Links
Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Date:4/28/2008

million in the prior year period, an increase of 4% that resulted primarily from two factors: increased reimbursement from Novartis of shared development expenses in the companies' blood screening collaboration; and increased reimbursement from 3M related to the companies' collaboration to develop rapid tests for healthcare-associated infections. These increases were partially offset by a reduction in funds received from the U.S. Department of Defense for prostate cancer research.

Royalty and license revenues for the first quarter of 2008 were $18.6 million, compared to $11.5 million in the prior year period. As previously discussed, this increase resulted primarily from $16.4 million of revenue from Bayer, which represents the third and final payment due in connection with the 2006 settlement of the companies' patent infringement litigation. In the prior year period, royalty and license revenues included $10.3 million from Bayer.

Gross margin on product sales in the first quarter of 2008 was 67.8%, compared to 66.5% in the prior year period. This improvement resulted primarily from increased sales of the APTIMA Combo 2 assay and from commercial pricing of the PROCLEIX WNV assay on the TIGRIS system in the United States. These benefits were partially offset by increased instrument sales, as described above.

Research and development (R&D) expenses in the first quarter of 2008 were $23.1 million, compared to $20.3 million in the prior year period, an increase of 14%. This increase resulted primarily from costs associated with key development programs such as the post-marketing studies of the PROCLEIX ULTRIO assay in the United States, the investigational APTIMA(R) human papillomavirus (HPV) assay, and Gen-Probe's fully automated instrument system for low- and mid-volume labs, known as PANTHER.

Marketing and sales expenses in the first quarter of 2008 were $11.9 million, compared to $9.5 million in the prior year period, an increase of 25%
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Gen-Probe to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
2. Gen-Probe to Webcast Presentations at Lehman and Cowen Healthcare Conferences
3. Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
4. Carl Hull Named President and Chief Operating Officer of Gen-Probe
5. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
6. Gen-Probe to Webcast Three Upcoming Presentations
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
9. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
10. CV Therapeutics Reports 2008 First Quarter Financial Results
11. Caliper Life Sciences Reports West Coast Consolidation of Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015  Centrillion ... a SBIR grant from the National Human ... Institutes of Health (NIH). The grant will ... in the development of breakthrough genomic technologies, ... specially fabricated substrates. Centrillion has been developing ...
(Date:4/17/2015)... SYDNEY , April 17, 2015  US-Australian drug ... signed a Memorandum of Understanding with the Feinstein ... New York to collaborate with ... cancers. The collaboration brings together the ... and clinical expertise of the Feinstein Institute in ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... , April 16, 2015  Schulman Associates IRB, ... technology, has signed a long-term lease on Laboratory Drive ... North Carolina . The location will house review ... to provide high quality reviews and customer service to ... represented Schulman in the deal, while Capital ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... FOLD ) today announced the election of ... Dr. Barer currently serves as Chairman and Chief ... veteran, Dr. Barer brings over 20 years of management ... leader who has helped transform Celgene into one of ...
... BURLINGTON, Mass., Jan. 8 Palomar Medical Technologies, ... researcher and developer of light-based systems for cosmetic ... distribution agreement with the Swedish company Q-MED AB ... biotech/medical device company based in Uppsala, Sweden. ...
... AMGN ) will present at the 27th Annual ... on Monday, Jan. 12, 2009, at the Westin St. Francis ... Sharer will present at the conference. Live audio of the ... accessed from Amgen,s Web site, www.amgen.com , under Investors. ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Palomar and Q-MED AB Terminate International Distribution Agreement 2Palomar and Q-MED AB Terminate International Distribution Agreement 3Palomar and Q-MED AB Terminate International Distribution Agreement 4Palomar and Q-MED AB Terminate International Distribution Agreement 5
(Date:4/10/2015)... , April 10, 2015 ... addition of the "Security Competitive Profiles - NEC" ... http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to supply ... to the market, with a company focus on the ... anticipated. Winning opportunities in the ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
(Date:4/2/2015)... , April 2, 2015 ... Q1 2015 attributed to somewhat higher than 125 MSEK. ... the year-end report 2014 that revenues for Q1 2015 ... the company reported for Q4 2014. The operating result ... be negative. The complete interim report will as previously ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4Fingerprint Cards Revises Revenues for Q1 2015 2
... of death in Europe and early diagnosis is essential ... electrical activity in real time using an electrocardiogram (ECG) ... the nature of a problem. Some cardiac conditions need ... them to be away from their everyday environment for ...
... Research engineers and sleep medicine specialists from two ... to put innovative quantitative analysis, signal-processing technology and ... One of their recent findings is that ... to distinguish fibromyalgia patients from healthy controls. ...
... given quercetin, a naturally occurring substance found in fruits ... according to a study published by The American Physiological ... the susceptibility of mice to the flu, but quercetin ... chemical relative of resveratrol, is present in a variety ...
Cached Biology News:A home early warning system for cardiac patients 2What a sleep study can reveal about fibromyalgia 2What a sleep study can reveal about fibromyalgia 3Substance found in fruits and vegetables reduces likelihood of the flu 2Substance found in fruits and vegetables reduces likelihood of the flu 3
Rabbit polyclonal to TRPM8 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 79054 SwissProtID: Q3YFM7...
...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
DNA fragmentation factor & Inhibitor of CAD...
Biology Products: